Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss ticagrelor and aspirin vs. DAPT followed by aspirin monotherapy (GLOBAL LEADERS); rivaroxaban vs. placebo in HF patients (COMMANDER HF); PAD in critical limb ischemia; tafamidis in transthyretin amyloid cardiomyopathy (ATTR-ACT); percutaneous MV repair in secondary mitral regurgitation and reduced LVEF (MITRA-FR); and a simple risk model to predict CVD or MI in stable CAD (CLARIFY Registry).

Keywords: ESC18, ESC Congress

< Back to Listings